Apeloa Pharmaceutical Co.,Ltd
000739
Rang in Aktien
#4342
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aktienkurs
$3.06
Marktkapitalisierung
$3.55B
Veränderung (1 Tag)
-3.45%
Veränderung (1 Jahr)
43.57%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)
Kategorie
Healthcare
Gewinn für Apeloa Pharmaceutical Co.,Ltd (000739)
Gewinn im Jun 2026 TTM: $149.15M
Laut den aktuellen Finanzberichten von Apeloa Pharmaceutical Co.,Ltd betragen die aktuellen Gewinne des Unternehmens $149.15M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $170.18M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $146.72M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Apeloa Pharmaceutical Co.,Ltd von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $149.15M | -9.53% |
| 2024 | $164.85M | -3.13% |
| 2023 | $170.18M | 15.99% |
| 2022 | $146.72M | -16.29% |
| 2021 | $175.28M | 19.13% |
| 2020 | $147.13M | 61.66% |
| 2019 | $91.01M | 35.45% |
| 2018 | $67.19M | 28.72% |
| 2017 | $52.20M | 8.08% |
| 2016 | $48.30M | 26.97% |
| 2015 | $38.04M | -37.54% |
| 2014 | $60.90M | 79.55% |
| 2013 | $33.92M | 25.69% |
| 2012 | $26.99M | 83.30% |
| 2011 | $14.72M | 255.37% |
| 2010 | $4.14M | -25.11% |
| 2009 | $5.53M | 37.62% |
| 2008 | $4.02M | -6.10% |
| 2007 | $4.28M | -48.53% |
| 2006 | $8.32M | 30.32% |
| 2005 | $6.38M | 8.44% |
| 2004 | $5.89M | -2.73% |
| 2003 | $6.05M | -2.07% |
| 2002 | $6.18M | -300.22% |
| 2001 | $-3.09M | 423.46% |
| 2000 | $-589.59K | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,083.07% |
IN
|
